Full-Time

Quality Assurance Operations Specialist 2

Maravai LifeSciences

Maravai LifeSciences

51-200 employees

Offers oligonucleotide synthesis and immunohistochemistry

Compensation Overview

$60k - $70k/yr

+ Equity + Bonus

San Diego, CA, USA

In Person

On-site role based in San Diego, California.

Bachelor's

Category
QA & Testing (1)
Required Skills
NetSuite
ISO 9001

Get referred to Maravai LifeSciences

See people who can refer or advise you

Requirements
  • Minimum, Bachelor's Degree in scientific discipline (Chemistry, Biology, Bioengineering, etc.).
  • Quality professional with a minimum of 5 years relevant experience in a life science industry.
  • Requires knowledge of ISO 9001 standards (or ISO 13485).
  • Strong and effective verbal and written communication skills.
  • Strong interpersonal, teamwork, and customer interfacing skills.
  • Strong problem-solving skills and analytical skills applied to investigations.
  • Self-motivated and able to organize and prioritize multiple tasks.
  • Ability to identify quality issues/discrepancies and effectively resolve discrepancies within the organization.
  • Proficient in Microsoft Office.
  • Experience with NetSuite ERP and MasterControl is a plus.
Responsibilities
  • Responsible for reviewing and approving Quality Events (e.g. discovery events and CAPAs) to ensure appropriate investigations are completed in a timely manner.
  • Provide oversight for quality operations training program and conducts quality related training.
  • Conduct quality investigations to assess root cause, corrections, corrective actions, preventive actions, and monitor effectiveness. Use of quality tools, such as 5-Why's, FMEA's, DMAIC, Cause and Effect Diagrams, Process Mapping, etc.
  • Lead cross-functional teams in risk identification and mitigation activities.
  • Review and approve product documentation for disposition of finished goods.
  • Review and approve change controls of materials, equipment, processes, and procedures including appropriate documentation.
  • Maintain the control of documents and records.
  • Assure compliance with all in-house or external specifications to standards such as ISO or customer requirements.
  • Work with various functions, including Manufacturing, QC, R&D, commercial, customer service, technical support, facilities, IT, etc. to continuously improve Quality Operations.
  • Lead Quality improvement projects.
  • Identify quality issues/discrepancies and effectively resolve these issues within the organization.
  • Manage document change orders and work with respective manufacturing and other teams to update procedures, work instructions, and forms as required.
  • Review stability protocols and packets as necessary.
  • Review finished good specifications.
  • Participate in project initiatives at the site as a quality representative.
  • Participate in internal and external audits as required.
  • Ensure compliance with GDP practices.
  • Promote a culture of quality, compliance, continuous improvement, and inspection readiness throughout the organization.
  • Perform other functions and duties as required.
Desired Qualifications
  • Experience with NetSuite ERP and MasterControl is a plus.

Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Get referred to Maravai LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 40.5% to $65.8 million, and guidance increased.
  • Q2 2026 revenue reached $51.4 million, while adjusted EBITDA rose to $8.7 million.
  • Refinancing extended debt maturity to 2032, giving Maravai flexibility for 2026 investments.

What critics are saying

  • Maravai’s February 2025 revenue-restatement scandal exposed internal-control failures and goodwill issues.
  • The August 2025 restructuring cut 25% of staff, risking execution gaps through Q3 2026.
  • COVID CleanCap demand remains volatile; a sustained drop destroys TriLink’s growth engine.

What makes Maravai LifeSciences unique

  • TriLink’s July 20, 2026 CleanCap patents secure dominant mRNA capping IP globally.
  • Cygnus’s mock viral particle technology shields bioprocess testing from direct reagent commoditization.
  • Officinae Bio’s February 24, 2025 acquisition adds AI-enabled mRNA design to TriLink.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Company Equity

Fertility Treatment Support

Family Planning Benefits

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Business Wire
Jun 23rd, 2026
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today anno...

Maravai LifeSciences Holdings, Inc.
Jun 9th, 2026
Maravai LifeSciences Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders

SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of…...

Maravai LifeSciences Holdings, Inc.
Jun 9th, 2026
424B4

The selling stockholders named in this prospectus are offering 20,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders.

MarketScreener
Jun 3rd, 2026
Maravai LifeSciences cuts debt to $150M and extends maturity to 2032

Maravai LifeSciences has refinanced its credit agreement, securing a $150 million term loan facility and a $30 million revolving credit facility. The life science reagents provider used the new term loan borrowings and approximately $98.5 million in cash to prepay its existing credit agreement due in October 2027. The transaction reduces Maravai's long-term debt from $242.9 million to $150 million and extends the maturity date to June 2032. Chief Financial Officer Raj Asarpota said the refinancing strengthens the company's financial foundation whilst preserving capital access for strategic priorities and growth initiatives. Maravai provides critical products for drug therapy development, diagnostics and vaccine research, serving major biopharmaceutical, vaccine and cell and gene therapy companies globally.

Associated Press
May 7th, 2026
Maravai LifeSciences raises 2026 guidance after Q1 revenue jumps 40.5% to $65.8M

Maravai LifeSciences, a global provider of life science reagents and services, reported first quarter 2026 revenue of $65.8 million, up 40.5% year-over-year, driven by strong demand in its TriLink business. The company posted a net loss of $6.4 million but achieved adjusted EBITDA of $20.3 million and returned to positive free cash flow, generating $4.2 million. TriLink revenue grew 65% to $47.5 million, including $14.3 million from COVID vaccine programme orders. Excluding COVID-related sales, TriLink base revenue increased 15% year-over-year. Cygnus revenue rose 1.4% to $18.4 million. Following the strong performance, Maravai raised its full-year 2026 guidance, now expecting revenue of $205 million to $215 million and adjusted EBITDA of $30 million to $32 million.